SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kjell Fuxe, Diego Guidolin, Luigi F Agnati, Dasiel O Borroto-Escuela, Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease, Expert Opinion on Therapeutic Targets, 2015, 19, 3, 377

    CrossRef

  2. 2
    Sophie Drapier, Marc Vérin, La maladie de Parkinson, 2015,

    CrossRef

  3. 3
    Fabio Blandini, Marie-Therese Armentero, Dopamine receptor agonists for Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 3, 387

    CrossRef

  4. You have free access to this content4
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  5. 5
    Manfred Gerlach, Paul Halley, Peter Riederer, Maarten van den Buuse, The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson’s disease: differential role of α2 adrenergic mechanisms, Journal of Neural Transmission, 2013, 120, 1, 31

    CrossRef

  6. 6
    Horst Baas, Wo stehen wir nach 100 Jahren mit L-Dopa?, DNP - Der Neurologe und Psychiater, 2012, 13, 3, 61

    CrossRef

  7. 7
    Robert A. Hauser, Peggy Auinger, Determination of minimal clinically important change in early and advanced Parkinson's disease, Movement Disorders, 2011, 26, 5
  8. 8
    Shin Hisahara, Shun Shimohama, Dopamine Receptors and Parkinson's Disease, International Journal of Medicinal Chemistry, 2011, 2011, 1

    CrossRef

  9. 9
    M. Vérin, La maladie de Parkinson, 2011,

    CrossRef

  10. 10
    Santiago Perez-Lloret, Olivier Rascol, Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease, CNS Drugs, 2010, 24, 11, 941

    CrossRef

  11. 11
    Olivier Rascol, Paolo Barone, Robert A. Hauser, Yoshikuni Mizuno, Werner Poewe, Anthony H.V. Schapira, Laurence Salin, Mandy Sohr, Catherine Debieuvre, Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease, Movement Disorders, 2010, 25, 14
  12. 12
    Mark J. Millan, From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease, Pharmacology & Therapeutics, 2010, 128, 2, 229

    CrossRef

  13. 13
    Olivier Rascol, Jean-Philippe Azulay, Olivier Blin, Anne-Marie Bonnet, Christine Brefel-Courbon, Pierre Césaro, Philippe Damier, Bérengère Debilly, Frank Durif, Monique Galitzky, Jean-Marie Grouin, Sylvie Pennaforte, Gabriel Villafane, Sadek Yaici, Yves Agid, Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo-controlled, randomized, double-blind, cross-over study, Movement Disorders, 2010, 25, 3
  14. 14
    Mauricette Brocco, Anne Dekeyne, Mariusz Papp, Mark J. Millan, Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors, Behavioural Pharmacology, 2006, 17, 7, 559

    CrossRef

  15. 15
    Olivier Rascol, Bruno Dubois, Alexandre Castro Caldas, Stephen Senn, Susanna Del Signore, Andrew Lees, Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study, Movement Disorders, 2006, 21, 12
  16. 16
    Anette Schrag, Cristina Sampaio, Nicholas Counsell, Werner Poewe, Minimal clinically important change on the unified Parkinson's disease rating scale, Movement Disorders, 2006, 21, 8
  17. 17
    Stéphane Thobois, Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: A review of the literature, Clinical Therapeutics, 2006, 28, 1, 1

    CrossRef

  18. You have free access to this content18
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  19. 19
    Lance A. Smith, Michael J. Jackson, Louisa Johnston, Mikko Kuoppamaki, Sarah Rose, Ghassan Al-Barghouthy, Susanna Del Signore, Peter Jenner, Switching from Levodopa to the Long-acting Dopamine D2/D3 Agonist Piribedil Reduces the Expression of Dyskinesia While Maintaining Effective Motor Activity in MPTP-treated Primates, Clinical Neuropharmacology, 2006, 29, 3, 112

    CrossRef

  20. 20
    Alexandre Castro-Caldas, Paul Delwaide, Wolfgang Jost, Marcelo Merello, Adrian Williams, Paolo Lamberti, Miguel Aguilar, Susanna Del Signore, Pierre Cesaro, The Parkinson–Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease, Movement Disorders, 2006, 21, 4
  21. 21
    Christopher G. Goetz, Werner Poewe, Olivier Rascol, Cristina Sampaio, Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004, Movement Disorders, 2005, 20, 5
  22. 22
    Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen, Treatment of motor dysfunction in Parkinson's disease: an overview, Clinical Neurology and Neurosurgery, 2005, 107, 4, 269

    CrossRef

  23. 23
    André Nieoullon, Antoine Coquerel, Dopamine, Current Opinion in Neurology, 2003, 16, S3

    CrossRef

  24. 24
    Ron Tintner, Joseph Jankovic, Dopamine agonists in Parkinson’s disease, Expert Opinion on Investigational Drugs, 2003, 12, 11, 1803

    CrossRef

  25. 25
    Virgilio Gerald H. Evidente, Raymund P. Esteban, Francis M. Domingo, Lourdjean O. Carbajal, Mercedita A. Parazo, Piribedil as an adjunct to levodopa in advanced Parkinson's disease: the Asian experience, Parkinsonism & Related Disorders, 2003, 10, 2, 117

    CrossRef

  26. 26
    Paul Tuite, Jennifer Riss, Recent developments in the pharmacological treatment of Parkinson’s disease, Expert Opinion on Investigational Drugs, 2003, 12, 8, 1335

    CrossRef

  27. 27
    Rebecca Stowe, Natalie Ives, Carl E Clarke, van Hilten, Joaquim Ferreira, Robert J Hawker, Laila Shah, Keith Wheatley, Richard Gray, Dopamine agonist therapy in early Parkinson's disease, The Cochrane Library,
  28. 28
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Early (Uncomplicated) Parkinson's Disease,